Charles Schwab
TBIO

Charles Schwab’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Charles Schwab’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-524,805
Closed -$14.5M – 3580
2021
Q2 		$14.5M Sell
524,805
-23,279
-4% -$457K ﹤0.01% 1798
2021
Q1 		$9.04M Buy
548,084
+24,854
+5% +$566K ﹤0.01% 2012
2020
Q4 		$9.64M Buy
523,230
+68,912
+15% +$1.23M ﹤0.01% 1890
2020
Q3 		$6.18M Buy
454,318
+326,084
+254% +$5.03M ﹤0.01% 1971
2020
Q2 		$2.3M Buy
128,234
+36,733
+40% +$554K ﹤0.01% 2377
2020
Q1 		$913K Buy
91,501
+5,325
+6% +$43.6K ﹤0.01% 2513
2019
Q4 		$702K Buy
86,176
+11,846
+16% +$109K ﹤0.01% 2708
2019
Q3 		$737K Hold
74,330
– – ﹤0.01% 2658
2019
Q2 		$939K Buy
74,330
+8,892
+14% +$93.7K ﹤0.01% 2593
2019
Q1 		$667K Buy
65,438
+46,848
+252% +$359K ﹤0.01% 2664
2018
Q4 		$140K Hold
18,590
– – ﹤0.01% 3063
2018
Q3 		$186K Buy
+18,590
New +$216K ﹤0.01% 3083

Charles Schwab's TBIO Position: Q3 2021 in Review

Charles Schwab sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 524,805 shares — an estimated $14.5M sold.

Charles Schwab first reported a position in TBIO in Q3 2018 and held it in 12 quarters. The position peaked at $14.5M in Q2 2021. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.

  • Charles Schwab reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Charles Schwab sold 524,805 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $14.5M.
  • Charles Schwab first reported a position in Translate Bio, Inc. Common Stock in Q3 2018 and held it in 12 quarters.
  • Charles Schwab's Translate Bio, Inc. Common Stock position peaked at $14.5M in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.

Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.